2014年度专利复审无效十大案件

2015-05-11 知识产权报 知识产权报

编者按:4月27日,在国家知识产权局开放日活动中,国家知识产权局专利复审委员会(下称专利复审委)经精心组织、认真评选,发布了2014年度专利复审无效十大案件,其中包括发明、实用新型、外观设计专利权无效宣告请求案以及发明专利申请复审请求案。这些案件或社会关注度高,或对相关行业产业有重大影响,或涉及重大疑难法律问题和重要审查标准。 专利复审委此次评选产生的十大案件,覆盖了机械、电学、通信、医

编者按:4月27日,在国家知识产权局开放日活动中,国家知识产权局专利复审委员会(下称专利复审委)经精心组织、认真评选,发布了2014年度专利复审无效十大案件,其中包括发明、实用新型、外观设计专利权无效宣告请求案以及发明专利申请复审请求案。这些案件或社会关注度高,或对相关行业产业有重大影响,或涉及重大疑难法律问题和重要审查标准。

专利复审委此次评选产生的十大案件,覆盖了机械、电学、通信、医药、化学、材料和外观设计等技术领域。这些案件是专利复审委员会按照客观、公正、准确、及时的要求,依法审查的结果,充分地体现了专利复审委员会“敬畏法律、注重责任、把握实质、执行一致”的审查理念。

知识产权报特专版刊登2014年度专利复审无效十大案件,以飨读者。

①“具有位置可变的平衡重的移动式提升起重机”发明专利权无效宣告请求案

专利权人:马尼托瓦克起重机有限公司

无效宣告请求人:三一重工股份有限公司

【案情】

专利号为ZL200810092407.6的“具有位置可变的平衡重的移动式提升起重机”发明专利于2011年在中国获得授权,并享有两项美国优先权。三一重工股份有限公司针对该专利向专利复审委员会提起无效宣告请求。专利复审委员会经审理后作出第22307号无效决定,认定涉案专利权利要求1-23均不具备创造性,宣告其专利权全部无效。

【点评】

该案的双方当事人分别是美国及中国起重机行业的龙头企业。该案通过对该领域公知常识的分析认为,该领域技术人员在对比文件公开内容的基础上,结合其所掌握的公知常识,通过合乎逻辑的分析推理即可获得该专利所要求保护的技术方案。该案对于该领域技术人员的专业知识、能力运用及技术判断均具有一定的指导作用。

②“用抗ErbB2抗体治疗”发明专利权无效宣告请求案

专利权人:基因技术股份有限公司

无效宣告请求人:国内个人

【案情】

涉案专利涉及抗ErbB2抗体(即“赫赛汀”)的药物制品及其制备方法,专利号为ZL200610008639.X。2014年2月,国内一自然人针对该专利向专利复审委员会提出了无效宣告请求。专利复审委员会经审理后,以涉案专利权利要求书不具备创造性为由作出第23948号无效决定,宣告涉案专利权全部无效。

【点评】

涉案专利所要求保护的“赫赛汀”是第一个分子靶向的抗癌药,对于乳腺癌的治愈率达到95%,全球年销售额超过70亿美元,其专利权人系国际生物医药行业巨头,在中国围绕该抗癌药提交专利申请近40件,涉案专利为其中的核心专利之一。该案明确了医药生物领域中给药特征所限定的产品及相应制药用途权利要求创造性的审查思路和方法,对于此类权利要求审查标准的合理把握和标准执行一致具有一定的指导作用。

③“具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂”发明专利权无效宣告请求案

专利权人:深圳微芯生物科技有限责任公司

无效宣告请求人:亨特博士实验室有限公司

【案情】

该案件涉及中国自主创新药物西达本胺的化合物核心专利,专利号为ZL03139760.3。该药物在T细胞淋巴瘤的治疗方面有较好疗效,已于2014年12月获中国国家食品药品监督管理总局批准上市,目前已完成美国食品药品监督管理局的I期临床试验研究。针对该专利,无效请求人认为其不符合专利法第二十二条第三款等规定,应予宣告专利权无效。专利复审委员会组成5人合议组进行审理,在专利权人提交权利要求书修改文本的基础上,作出第24591号无效决定,维持涉案专利权有效。

【点评】

该案从一个侧面反映了中国制药行业开始由“中国制造”向“中国创造”转变,在制药行业具有深远影响。该案涉及无效阶段权利要求书的修改,审查中对相关审查规范进行了有益探索,对未来类似案件的审理及相关审查规范的完善有积极的借鉴和参考意义。

④“寻呼方法及装置”发明专利权无效

宣告请求案

专利权人:GPNE公司

无效宣告请求人:苹果电脑贸易(上海)有限公司、诺基亚(中国)投资有限公司

【案情】

专利号为ZL95190550.3的“寻呼方法及装置”发明专利申请于2001年获得授权。专利授权后,专利权人在中国、美国均针对苹果公司、诺基亚公司等通信企业巨头提起侵权诉讼。针对上述诉讼请求,苹果公司、诺基亚公司先后多次向专利复审委员会提起无效宣告请求。专利复审委员会经合并审理后作出第23050号无效决定,宣告涉案专利权部分无效。

【点评】

涉案专利主要涉及双向寻呼方法及系统,属于通信领域的基础专利,多家国际通信企业巨头多次对其提起无效宣告请求,且所涉及的侵权诉讼标的额高达数亿元,在通信领域具有重大影响。在该案审理过程中,专利复审委员会依据相关规定,根据说明书记载的技术内容,对权利要求书中的关键技术术语“请求使能信号”的含义进行解释,合理界定了权利要求的保护范围。该案对于相关领域类似案件的审查具有一定的指导作用。

⑤“粉末状澄清剂及将其混入半透明聚烯烃树脂中的方法”发明专利权无效宣告请求案


专利权人:美利肯公司

无效宣告请求人:广州呈和科技有限公司、淄博润源化工有限公司、国内个人

【案情】

专利号为ZL93105006.5,名称为“粉末状澄清剂及将其混入半透明聚烯烃树脂中的方法”的专利在中国获得授权后,先后经历了8次无效宣告请求。专利复审委员会经审理后作出第23770号无效决定,维持涉案专利权有效。

【点评】

涉案专利自1999年授权之日起,就受到行业内的高度关注。在涉案专利的无效宣告程序中,上述三个无效宣告请求人和专利权人提交了相同的公知常识性证据,但对于证据公开内容的解读以及在证据的使用方式上存在分歧。合议组在认真考量该证据中对于重要技术信息的描述后认为,查证引证原文的信息是必要的,从而作出维持专利权有效的审查决定。该案对于准确认定公知常识性证据所公开的内容具有一定的指导作用和借鉴意义。

⑥“预应力高强混凝土方桩及其制造方法和成型模具”发明专利权无效宣告请求案

专利权人:上海中技桩业股份有限公司

无效宣告请求人:国内个人

【案情】

专利号为ZL200710068545.6的“预应力高强混凝土方桩及其制造方法和成型模具”发明专利授权后,9家企业及个人先后共14次向专利复审委员会提起专利权无效宣告请求,专利复审委员会先后作出包含该案在内的7个无效决定,该案涉及第21471号无效决定,维持涉案专利权有效。

【点评】

涉案专利授权后受到业内广泛关注,成为助推中小企业快速成长的核心技术,在建筑领域具有突出的市场价值,对该案的审理也受到了建筑行业的普遍关注。专利复审委员会在案件审理过程中以发明构思为切入点,从技术方案实际解决的技术问题、采用的技术手段以及取得的技术效果三个方面分析了现有技术与涉案专利的不同,对于该技术领域创造性的审查实践具有一定的指导作用和借鉴意义。

⑦“一种透明导电膜及其制作方法”发明专利权无效宣告请求案

专利权人:苏州苏大维格光电科技股份有限公司、苏州大学

无效宣告请求人:国内个人

【案情】

申请号为ZL201010533228.9的“一种透明导电膜及其制作方法”的发明专利于2013年获得授权,专利权人苏州苏大维格光电科技股份有限公司为中国在微纳米领域拥有自主创新技术的代表性企业之一。针对该专利,请求人于2014年5月16日向专利复审委员会提出无效宣告请求。经审查,专利复审委员会作出第24621号无效决定,维持涉案专利权有效。

【点评】

涉案专利涉及采用微纳米图形化和纳米压印技术成功实现量产大尺寸透明导电膜的核心技术,提供了一种非ITO透明导电薄膜的新型制造方法,为专利权人在微纳米制造领域的核心专利之一,是低成本制造大尺寸透明导电膜领域的一项重要技术突破。专利复审委员会清晰把握发明实质,客观认定案件事实,准确适用法律法规,作出维持专利权有效的审查决定。该案的审理对于中国微纳米制造领域产业的未来发展具有重要影响。

⑧“电容式触控板的触控图型结构”实用新型专利权无效宣告请求案

专利权人:宸鸿光电科技股份有限公司

无效宣告请求人:深圳欧菲光科技股份有限公司、诺基亚通信有限公司、东莞万士达液晶显示器有限公司

【案情】

涉案专利的专利号为ZL200720142844.5,名称为“电容式触控板的触控图型结构”,专利权人于2013年1月针对上述无效宣告请求人提出专利侵权诉讼,要求其中两被告分别赔偿6060万元和2690万元。专利复审委员会经合案审理后作出第21304号无效决定,宣告涉案专利权全部无效。

【点评】

该案的专利权人和请求人均是全球主要的透射式电容式触控屏生产商,该案被视为对移动互联终端产业链上游厂商具有深远意义的标志性案件。专利复审委员会在案件审理过程中,对权利要求的保护范围进行了合理界定。对于已在现有技术中普遍存在,但不具有特定名称的部件,认定其名称的变换不能影响该领域技术人员对其功能、作用的认识。该案对类似案件的审理具有一定的指导作用。

⑨“汽车(SUV)”外观设计专利权无效

宣告请求案

专利权人:江苏金湖欧陆汽车有限公司

无效宣告请求人:大众汽车公司

【案情】

请求人于2012年在巴西圣保罗车展中推出“Taigun”概念车,同年获得世界知识产权组织(WIPO)的注册外观设计。次年,专利权人在中国提出名称为“汽车(SUV)”的ZL201330096428.7号外观设计专利申请,并获得授权。2014年,请求人启动无效程序,认为涉案专利相对于请求人在WIPO注册的外观设计不符合专利法第二十三条第二款的规定。专利复审委员会经审理后作出第24267号无效决定,宣告涉案专利权全部无效。

【点评】

该案以功能和美学设计并重的汽车类产品为例,强调外观设计专利保护的是满足一定创新高度的发明创造,明确了不同设计特征对于整体视觉效果应有不同影响权重。在外观设计无效案件审理过程中,应以现有设计状况为依据,客观区分产品中的创新性特征和非创新性特征,遵循整体观察、综合判断的原则,在考虑创新性设计特征较大权重的同时不应忽略其他设计特征,并基于产品的全部设计特征,综合分析、科学得出结论。该案深入诠释了“明显区别”判断的客观审查标准,对于同类案件的审理具有一定的指导作用。

⑩“使胺催化剂在界面聚碳酸酯生产工艺中再循环的方法”发明专利申请复审请求案

复审请求人:思迪隆欧洲有限公司

【案情】

涉案专利的申请号为200980146668.4,涉及使胺催化剂在界面聚碳酸酯生产工艺中再循环的方法。2012年12月,经实质审查后,以不符合专利法第二十二条第三款有关创造性的规定为由驳回了涉案专利申请。申请人不服,向专利复审委员会提出了复审请求。复审阶段,专利复审委员会对区别特征和发明实际解决的技术问题进行了重新分析确定,并依职权引入了公知常识性证据对该案的创造性进行了充分说理。复审请求人在指定期限内放弃答复,涉案专利申请被视为撤回。

【点评】

聚碳酸酯性能优越、应用广泛。该案是对聚碳酸酯主流制备方法的改进——在洗涤步骤之后,用碱性溶液处理酸性洗涤液,并调整其pH值以获得碱性洗涤水溶液,并将其再循环到聚合步骤中。该案是在复审过程中依职权引入公知常识性证据的典型案例,该案件的审理对中国聚碳酸酯工业的发展具有重要影响。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=56223, encodeId=924f56223f4, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56224, encodeId=c835562249a, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56225, encodeId=6a6f5622517, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56226, encodeId=cfe556226c2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56227, encodeId=04985622ed9, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56215, encodeId=c4555621572, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56216, encodeId=a82156216d3, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56217, encodeId=f1565621ecd, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56218, encodeId=c13956218c1, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56219, encodeId=bd705621971, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    嗯,

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=56223, encodeId=924f56223f4, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56224, encodeId=c835562249a, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56225, encodeId=6a6f5622517, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56226, encodeId=cfe556226c2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56227, encodeId=04985622ed9, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56215, encodeId=c4555621572, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56216, encodeId=a82156216d3, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56217, encodeId=f1565621ecd, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56218, encodeId=c13956218c1, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56219, encodeId=bd705621971, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    嗯,

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=56223, encodeId=924f56223f4, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56224, encodeId=c835562249a, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56225, encodeId=6a6f5622517, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56226, encodeId=cfe556226c2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56227, encodeId=04985622ed9, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56215, encodeId=c4555621572, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56216, encodeId=a82156216d3, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56217, encodeId=f1565621ecd, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56218, encodeId=c13956218c1, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56219, encodeId=bd705621971, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    好文章!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=56223, encodeId=924f56223f4, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56224, encodeId=c835562249a, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56225, encodeId=6a6f5622517, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56226, encodeId=cfe556226c2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56227, encodeId=04985622ed9, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56215, encodeId=c4555621572, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56216, encodeId=a82156216d3, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56217, encodeId=f1565621ecd, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56218, encodeId=c13956218c1, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56219, encodeId=bd705621971, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    好文章!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=56223, encodeId=924f56223f4, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56224, encodeId=c835562249a, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56225, encodeId=6a6f5622517, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56226, encodeId=cfe556226c2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56227, encodeId=04985622ed9, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56215, encodeId=c4555621572, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56216, encodeId=a82156216d3, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56217, encodeId=f1565621ecd, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56218, encodeId=c13956218c1, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56219, encodeId=bd705621971, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    好文章!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=56223, encodeId=924f56223f4, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56224, encodeId=c835562249a, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56225, encodeId=6a6f5622517, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56226, encodeId=cfe556226c2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56227, encodeId=04985622ed9, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56215, encodeId=c4555621572, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56216, encodeId=a82156216d3, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56217, encodeId=f1565621ecd, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56218, encodeId=c13956218c1, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56219, encodeId=bd705621971, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    过来看看,了解下,不错的,

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=56223, encodeId=924f56223f4, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56224, encodeId=c835562249a, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56225, encodeId=6a6f5622517, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56226, encodeId=cfe556226c2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56227, encodeId=04985622ed9, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56215, encodeId=c4555621572, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56216, encodeId=a82156216d3, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56217, encodeId=f1565621ecd, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56218, encodeId=c13956218c1, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56219, encodeId=bd705621971, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    过来看看,了解下,不错的,

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=56223, encodeId=924f56223f4, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56224, encodeId=c835562249a, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56225, encodeId=6a6f5622517, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56226, encodeId=cfe556226c2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56227, encodeId=04985622ed9, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56215, encodeId=c4555621572, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56216, encodeId=a82156216d3, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56217, encodeId=f1565621ecd, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56218, encodeId=c13956218c1, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56219, encodeId=bd705621971, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    ,感谢分享~~

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=56223, encodeId=924f56223f4, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56224, encodeId=c835562249a, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56225, encodeId=6a6f5622517, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56226, encodeId=cfe556226c2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56227, encodeId=04985622ed9, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56215, encodeId=c4555621572, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56216, encodeId=a82156216d3, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56217, encodeId=f1565621ecd, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56218, encodeId=c13956218c1, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56219, encodeId=bd705621971, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    ,感谢分享~~

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=56223, encodeId=924f56223f4, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56224, encodeId=c835562249a, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56225, encodeId=6a6f5622517, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56226, encodeId=cfe556226c2, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56227, encodeId=04985622ed9, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:07:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56215, encodeId=c4555621572, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56216, encodeId=a82156216d3, content=过来看看,了解下,不错的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56217, encodeId=f1565621ecd, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56218, encodeId=c13956218c1, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56219, encodeId=bd705621971, content=,感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:06:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    ,感谢分享~~

    0

相关资讯

知识产权将从“云端”走向大众

原标题:知识产权将从“云端”走向大众 知识产权不再是曲高和寡,而将成为人人都要了解的一项技能。昨天举行的上海市知识产权联席会议部署了2015年知识产权工作,其中全力以赴做好市委关于加快建设具有全球影响力的科技创新中心成为重中之重。上海市副市长赵雯表示,知识产权是创新的保障,在全面提倡“大众创业、万众创新”的今天,知识产权将从“云端”走向大众。 尽管本市去年专利申请总量同比下降5.5%,但4

专利申请的十一大误区

随着近几年国家对知识产权的重视,国内的企业对专利在提升核心竞争力方面的作用有了进一步的认识,纷纷加强了专利工作,专利申请量大幅度增加,但是在专利代理过程中,笔者发现不少企业在专利申请过程中,仍存在误区,需要早日改进。误区一:自主研发的成果不申请专利就有知识产权。一些技术人员认为只要是自主创新,就有了自主知识产权。其实不然,专利是一种垄断权,自主研发的技术成果如果不申请专利,就得不到法律确认和保

不丧失专利新颖性的宽限期

一、建议,尽量避免使用不丧失新颖性的宽限期虽然专利法规定了不丧失专利新颖性的宽限期,但小编认为尽量不使用它,原因是:首先对符合规定的展览或会议要求较高,而且必须能出具证明才有效,同时此种公开对自己和他人的技术都会有影响,即公开日并非专利申请日,因此,建议,最好在展出或发表自己的技术之前,先申请专利,获得申请日和申请号之后,再参加展出或会议发表等,这样才能有效保证自己技术的新颖性。如果出于其他原因产

在线课堂:科研工作与知识产权保护系列课程

知识产权也称其为“知识财产权”,是关于人类在社会实践中创造的智力劳动成果的专有权利,是一种无形财产权。它有两类:一类是著作权,也称为版权,另一类是工业产权,也称为产业产权,其中产业产权又主要包括专利权与商标权。知识产权保护是非常重要的。 本系列课程涵盖目前国家非常重视的知识产权领域中的专利问题,课程中江编辑将为大家细致的讲解科研工作者关于认知专利、运用专利等方面的知识,尤其涉及医学、药学以及

了解专利的官方审查流程

(一)发明专利的官方审查包括五阶段:受理阶段、初审阶段、公布阶段、实审阶段、授权阶段;1、发明专利的受理阶段时间:大约1个月左右;申请人获得专利受理通知书;如果通过电子提交方式申请专利,一般提交日的第二天即可获得申请日和申请号。流程:申请人提出专利申请 → 专利局受理(获得申请日和申请号) → 专利局下发专利受理通知书 → 申请人缴纳申请费(申请日起2个月内

宏观了解专利过程

引言:建议委托代理人完成专利申请工作;原因体现在:专利申请文件的撰写以及答复审查意见的形式较为专业;另外,专利申请提交方式、专利费用的缴纳以及各类程序的时间规定等方面较为繁琐。如下从专利申请—专利审查—专利授权—专利权维护—专利权终止等方面进行概述。一、专利申请前的准备工作申请人将自己的技术方案,以技术交底书的方式呈现给代理人,并提供相关基础信息,签订委托书和代理合同等文件;申请人支付代理服务费和